

22 June 2010

The Manager
Company Announcements Office
ASX Limited
20 Bridge St
SYDNEY, NSW, 2000

Dear Sir,

RESULTS OF GENERAL MEETING

We wish to advise that resolutions put to the General Meeting of CBio Limited held today were each passed on an unanimous show of hands.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution as follows:-

	Total number of votes	For the resolution	At proxy's discretion	Against resolution	Abstain from resolution
Resolution 1					
Approval of prior share and option issue	22,154,504	18,857,584	980,590	2,316,330	Nil
Resolution 2					
Approval of prior share issue	22,143,948	19,261,152	1,020,590	1,862,206	Nil
Resolution 3					
Approval of prior share issue	22,143,948	18,900,028	1,020,590	2,223,330	Nil

For and on behalf of the Board

BEN GRAHAM
Company Secretary

For further information:

Ben Graham
Company Secretary
CBio Limited
T: +61 7 3841 4844
ben.graham@cbio.com.au

About CBio:

CBio is an Australian ASX listed company established in 2000. CBio's lead product XToll is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis. It is currently being trialled in phase II clinical trials in patients with rheumatoid arthritis (RA). Global sales of RA therapies exceeded US\$17 billion in 2008.

Novo Nordisk A/S, a top 20 global pharmaceutical company and world-leader in diabetes care, has an exclusive option to enter into a licence agreement for the intellectual property rights relating to XToll.

CBio's Board includes internationally experienced drug developers including Dr Goran Ando, Vice-Chairman Novo Nordisk A/S (formerly president of R&D at Pharmacia/Pfizer and R&D director of Glaxo Group, UK); Dr Peter Corr, Founder and co-General Partner of Celtic Therapeutics (formerly Senior Vice-President for Science and Technology at Pfizer and Chairman of the Board of Governors, New York Academy of Sciences); and Professor John Funder, AO, Professor of Medicine at Monash University, Senior Fellow at Prince Henry's Institute of Medical Research (formerly Director of the Baker Institute, 1990-2001).